Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000231520 | SCV000288220 | uncertain significance | Baller-Gerold syndrome | 2024-12-31 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 806 of the RECQL4 protein (p.Gly806Glu). This variant is present in population databases (rs762456224, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with RECQL4-related conditions. ClinVar contains an entry for this variant (Variation ID: 239726). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt RECQL4 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001753701 | SCV001987775 | uncertain significance | not provided | 2020-05-08 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV002478862 | SCV002794050 | uncertain significance | Baller-Gerold syndrome; Rapadilino syndrome; Rothmund-Thomson syndrome type 2 | 2022-04-20 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004532896 | SCV004116127 | uncertain significance | RECQL4-related disorder | 2024-02-07 | no assertion criteria provided | clinical testing | The RECQL4 c.2417G>A variant is predicted to result in the amino acid substitution p.Gly806Glu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.028% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |